

Regimen Reference Order – GAST – trastuzumab + XELOX

ARIA: GAST – [trastuzumab + XELOX (MET)]

Planned Course: Every 21 days for 6 cycles

Indication for Use: Gastric Cancer/Gastroesophageal Junction Tumor; HER2 positive; Metastatic

CVAD: At Provider’s Discretion

Proceed with treatment if:

ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GAST – trastuzumab + XELOX

Drug	Dose	CCMB Administration Guideline
Establish primary solution 500 mL of: normal saline (trastuzumab incompatible with D5W)		
trastuzumab (brand name specific)	Cycle 1 8 mg/kg Loading Dose	IV in normal saline 250 mL over 90 minutes <i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i> <i>*Nursing Alert: oxaliplatin infusion begins after observation period is complete</i>
	Cycles 2 to 6 6 mg/kg	IV in normal saline 250 mL over 30 minutes <i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i>
Establish primary solution 500 mL of: D5W (oxaliplatin incompatible with normal saline)		
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy
oxaliplatin	130 mg/m^2	IV in 500 mL D5W over 2 hours
capecitabine	1000 mg/m^2	Orally twice a day on Days 1 – 14 followed by 7 days off (Self-administered at home)
capecitabine (Xeloda®) available dosage strengths: 150 mg and 500 mg tablets		
Classification of capecitabine: Cytotoxic, Hazardous		
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See GAST or THOR DSG – Dose Banding document for more information		

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Cardiac monitoring

- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and every 4 cycles

All Cycles

- CBC, biochemistry and liver enzymes as per Physician Orders

Cycle 1 Only

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after trastuzumab infusion. Full vital signs after observation period is complete. oxaliplatin infusion begins after observation period is complete
- Patient can be discharged from treatment room if stable whether they had a reaction or not

Cycles 2 to 6

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
dexamethasone	8 mg	Orally once daily on Days 2 and 3
prochlorperazine	10 mg	Orally every 6 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- capecitabine can cause diarrhea, hand-foot syndrome and neuropathy
- oxaliplatin causes cold intolerance and laryngopharyngeal dysesthesia
 - no ice chips or cold drinks
- oxaliplatin may cause progressive, irreversible neuropathy
 - dose modification may be required
- trastuzumab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after trastuzumab. **Ensure prescription label matches the brand name on prescribed order**